Editas Medicine Inc (EDIT) Insider Katrine Bosley Sells 8,333 Shares

Editas Medicine Inc (NASDAQ:EDIT) insider Katrine Bosley sold 8,333 shares of the firm’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $29.58, for a total transaction of $246,490.14. Following the transaction, the insider now owns 1,387,897 shares of the company’s stock, valued at approximately $41,053,993.26. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Katrine Bosley also recently made the following trade(s):

  • On Wednesday, November 1st, Katrine Bosley sold 8,333 shares of Editas Medicine stock. The stock was sold at an average price of $23.64, for a total transaction of $196,992.12.
  • On Monday, October 2nd, Katrine Bosley sold 8,333 shares of Editas Medicine stock. The stock was sold at an average price of $24.78, for a total transaction of $206,491.74.

Editas Medicine Inc (NASDAQ:EDIT) traded down $0.47 during trading hours on Wednesday, hitting $27.29. 931,900 shares of the stock were exchanged, compared to its average volume of 925,975. Editas Medicine Inc has a 52 week low of $13.12 and a 52 week high of $31.81. The company has a debt-to-equity ratio of 0.19, a current ratio of 10.12 and a quick ratio of 10.12.

Editas Medicine (NASDAQ:EDIT) last posted its earnings results on Tuesday, November 7th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.04). Editas Medicine had a negative net margin of 1,127.03% and a negative return on equity of 70.19%. The firm had revenue of $6.28 million during the quarter, compared to the consensus estimate of $2.66 million. During the same quarter last year, the firm posted ($0.59) EPS. The business’s revenue was up 553.0% on a year-over-year basis. sell-side analysts anticipate that Editas Medicine Inc will post -2.92 EPS for the current year.

Several large investors have recently bought and sold shares of EDIT. IHT Wealth Management LLC bought a new position in shares of Editas Medicine in the second quarter valued at approximately $107,000. Great West Life Assurance Co. Can raised its position in Editas Medicine by 519.9% in the 3rd quarter. Great West Life Assurance Co. Can now owns 4,959 shares of the company’s stock worth $114,000 after purchasing an additional 4,159 shares during the last quarter. DekaBank Deutsche Girozentrale bought a new position in Editas Medicine in the 2nd quarter worth approximately $127,000. Bank of America Corp DE raised its position in Editas Medicine by 72.2% in the 1st quarter. Bank of America Corp DE now owns 5,936 shares of the company’s stock worth $133,000 after purchasing an additional 2,489 shares during the last quarter. Finally, Legal & General Group Plc raised its position in Editas Medicine by 308.4% in the 2nd quarter. Legal & General Group Plc now owns 8,654 shares of the company’s stock worth $145,000 after purchasing an additional 6,535 shares during the last quarter. Institutional investors own 70.11% of the company’s stock.

EDIT has been the subject of a number of analyst reports. Barclays initiated coverage on shares of Editas Medicine in a research note on Wednesday, September 6th. They set an “overweight” rating and a $28.00 price target for the company. Zacks Investment Research upgraded shares of Editas Medicine from a “hold” rating to a “buy” rating and set a $25.00 price target for the company in a research note on Friday, November 10th. ValuEngine cut shares of Editas Medicine from a “hold” rating to a “sell” rating in a research note on Wednesday, October 25th. Cowen restated a “buy” rating on shares of Editas Medicine in a research note on Tuesday, November 7th. Finally, Cann reiterated a “hold” rating on shares of Editas Medicine in a research note on Tuesday, November 7th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $26.73.

WARNING: “Editas Medicine Inc (EDIT) Insider Katrine Bosley Sells 8,333 Shares” was first published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this article on another domain, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this article can be read at https://ledgergazette.com/2017/12/06/editas-medicine-inc-edit-insider-katrine-bosley-sells-8333-shares.html.

Editas Medicine Company Profile

Editas Medicine, Inc is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology.

Insider Buying and Selling by Quarter for Editas Medicine (NASDAQ:EDIT)

Receive News & Ratings for Editas Medicine Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply